Description
RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat
Article: RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat
€3.03
Reviews
There are no reviews yet.